Enterprises are transitioning from initial AI deployments to embedding AI as a core capability. The focus has shifted from merely improving efficiency to fundamentally transforming operations through AI. This evolution is expected to lead to a significant increase in global AI spending, reaching $337 billion by 2025.
AI's integration into life sciences R&D is particularly promising, with generative AI enhancing processes like regulatory submissions and drug discovery. Other industries, such as aerospace and food production, showcase the potential of AI in improving safety and quality control. As organizations modernize their IT infrastructures, the emphasis on rich, reliable data will be crucial for maximizing AI's impact.
• AI spending is projected to reach $337 billion by 2025.
• Generative AI is transforming life sciences R&D processes.
Generative AI refers to algorithms that can create new content, enhancing processes like regulatory submissions.
RWD consists of patient health data that informs ongoing drug safety monitoring and potential new treatment uses.
RWE is derived from analyzing RWD, reinforcing clinical trial findings and informing biopharma propositions.
ArisGlobal is a technology company focused on life sciences, leveraging AI to streamline R&D processes.
United Nations Regional Information Centre 11month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
